Orexigen Therapeutics Inc., of San Diego, reported fourth quarter revenue of $4.9 million, which included $2.6 million in royalties earned on U.S. net sales of Contrave of $13 million reported by their U.S. partner, Takeda Pharmaceuticals U.S.A. Inc., part of Takeda Pharmaceuticals Co. Ltd., of Osaka, Japan.